Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanogam 100 mg/ml pharmacokinetics and safety study
2012-005727-32Phase 3Completed
- Sponsor
- Sanquin
- Start
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Nanogam in primary hypogammaglobulinemia, agammaglobulinemia and common variable immunodeficiency (CVID) (2 arms), sponsored by Sanquin. Primary endpoint: Pharmacokinetic bioequivalence. Started May 2013; status: completed.
02
Drugs
Nanogam
03
Conditions
primary hypogammaglobulinemiaagammaglobulinemiacommon variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2012-005727-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005727-32.